Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -22.05
- Piotroski Score 2.00
- Grade Buy
- Symbol (PYPD)
- Company PolyPid Ltd.
- Price $3.55
- Changes Percentage (7.1%)
- Change $0.24
- Day Low $3.35
- Day High $3.62
- Year High $9.20
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $10.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$9.89
- Trailing P/E Ratio -0.44
- Forward P/E Ratio -0.44
- P/E Growth -0.44
- Net Income $-23,865,000
Income Statement
Quarterly
Annual
Latest News of PYPD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
The Shield 2 trial's blinded infection rate aligns with expectations, with most patients outside the US. A P-value of 0.01 or lower is needed to stop for efficacy during the interim analysis, based on...
By Yahoo! Finance | 1 week ago
